TrialPharmacoEconomics2007

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Maureen P M H Rutten-van Mölken et al.PubMed ↗Publisher ↗

No numbers read from the abstract.